US Patent Office Grants Patent for COVID-19 Risk Test
Filed with ASX · · 2 pages · English
Melbourne, Australia, 23 February 2022:Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”),a global leader in genomics-based tests in health, wellness and serious disease is pleased to announce the granting of US Patent No: US 11,257,569, Methods of assessing risk of developing a severe response to Coronavirus infection. The granted US patent covers the proprietary technology i
Genetic Technologies Limited on 6ix
In the deck
Story so far
Earlier from Genetic Technologies
- GeneType Multi-Test Approved for Commercial Release
- Quarterly Activities Report & Appendix 4C
- Momentum Building with Cash Receipts up 112% for Q2 FY22
- GTG delivers material increase in cash receipts
- Presentation to H.C. Wainwright Investment Conference
Later from Genetic Technologies
- Half Year Report and Accounts
- Genetic Technologies 1H FY22 results
- Acquisition of Global Direct to Consumer Ecommerce Business
- Transformational Pathway to US Payer System
- GeneType Risk Assessment Test Onboarding in 16 clinics
Follow Genetic Technologies into a list and get an email when it puts out news.
Follow Genetic Technologies